RAS Peptide Profiles in Patients With Treatment-resistant Arterial Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-31

Study Completion Date

2017-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates RAS peptides profiles in patients with treatment resistant arterial hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19

NCT04351581

Covid-19

COMPLETED NA

Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects

NCT03001271

Hypertension

UNKNOWN EARLY_PHASE1

Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure

NCT00925470

Blood Pressure

COMPLETED

Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19

NCT04374695

COVID-19

UNKNOWN

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

NCT01658657

Hypertension Plasma Renin Activity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Selective quantification of RAS peptides in human plasma triggered investigations evaluating whether RAS peptides could be used as clinical biomarkers in patients receiving antihypertensive treatment.

Drug-specific RAS profiles first characterized in healthy normotensive subjects (EKBB 255/12; ClinicalTrials.gov ID NCT01771783) are presently investigated in patients with newly diagnosed arterial hypertension (EKNZ 2015-081; clinicaltrials.gov identifier (ID) NCT02449811). With this observational study RAS peptide profiles will be characterized in patients with treatment resistant hypertension. Data generated by this study will show whether RAS peptide profiles merit further evaluation as clinical biomarkers in this complex patient group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment-resistant hypertension

patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Office blood pressure ≥ 140/90 mmHg and mean 24 hour blood pressure \>130/80 mmHg on average, or \>135/85 mmHg during the day, or \> 120/70 mmHg during the night, despite concurrent use of 3 antihypertensive agents at optimal doses, including one diuretic OR
* Office blood pressure and 24 hour mean blood pressure controlled with four or more medications

* Age ≥ 18 years
* Ability to understand research procedures and to provide written informed consent

Exclusion Criteria

* Known secondary arterial hypertension at time of inclusion or diagnosis of secondary hypertension after study inclusion during routine work-up of treatment resistant hypertension
* Known obstructive sleep apnea at time of inclusion
* History of, or clinically relevant or uncontrolled cardiovascular disease (other than arterial hypertension), namely myocardial infarction within last 3 months or valvular heart disease with clinically relevant reflux or heart failure
* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the research project or compliance with the research plan.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No